Longview Partners Guernsey LTD Lowers Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Longview Partners Guernsey LTD reduced its stake in IQVIA Holdings Inc. by 5.8%, selling 124,168 shares, which now constitutes approximately 2.9% of its investment portfolio.
• IQVIA reported $2.81 earnings per share for the last quarter, surpassing analysts' expectations, and the company's revenue increased by 5.3% year-over-year.
• Seventeen investment analysts suggest a Buy rating for IQVIA, and the stock maintains a consensus target price of around $228.62.

Longview Partners Guernsey LTD lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,028,276 shares of the medical research company's stock after selling 124,168 shares during the quarter. IQVIA accounts for approximately 2.9% of Longview Partners Guernsey LTD's portfolio, making the stock its 23rd largest position. Longview Partners Guernsey LTD owned about 1.17% of IQVIA worth $357,585,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Continuum Advisory LLC increased its stake in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares in the last quarter. Ballentine Partners LLC increased its stake in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after purchasing an additional 69 shares in the last quarter. Independent Advisor Alliance increased its stake in IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after purchasing an additional 72 shares in the last quarter. ST Germain D J Co. Inc. grew its stake in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Finally, Nemes Rush Group LLC grew its stake in shares of IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after acquiring an additional 81 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Robert W. Baird upped their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Barclays upped their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Evercore ISI upped their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.07 during midday trading on Thursday, reaching $188.73. The company had a trading volume of 1,161,570 shares, compared to its average volume of 1,323,966. The company's 50 day moving average price is $176.32 and its 200 day moving average price is $167.99. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a market cap of $32.08 billion, a P/E ratio of 27.31, a P/E/G ratio of 2.07 and a beta of 1.30. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.